title: Biosynthesis of Fluorinated Analogs of Drugs Using Human Cytochrome P450 Enzymes Followed by Deoxyfluorination and Quantitative Nuclear Magnetic Resonance Spectroscopy to Improve Metabolic Stability.
abstract: Replacement of hydrogen with fluorine is a useful drug design strategy when decreases in cytochrome P450 (P450) metabolic lability are needed. In this paper, a facile two-step method of inserting fluorine into metabolically labile sites of drug molecules is described that utilizes less than 1 mg of starting material and quantitative NMR spectroscopy to ascertain the structures and concentrations of products. In the first step, hydroxyl metabolites are biosynthesized using human P450 enzymes, and in the second step these metabolites are subjected to deoxyfluorination using diethylaminosulfur trifluoride (DAST). The method is demonstrated using midazolam, celecoxib, ramelteon, and risperidone as examples and CYP3A5, 2C9, 1A2, and 2D6 to catalyze the hydroxylations. The drugs and their fluoro analogs were tested for metabolic lability. 9-Fluororisperidone and 4'-fluorocelecoxib were 16 and 4 times more metabolically stable than risperidone and celecoxib, respectively, and 2-fluororamelteon and ramelteon were metabolized at the same rate. 1'-Fluoromidazolam was metabolized at the same rate as midazolam by CYP3A4 but was more stable in CYP3A5 incubations. The P450-catalyzed sites of metabolism of the fluorine-containing analogs were determined. Some of the metabolites arose via metabolism at the fluorine-substituted carbon, wherein the fluorine was lost to yield aldehydes. In summary, this method offers an approach whereby fluorine can be substituted in metabolically labile sites, and the products can be tested to determine whether an enhancement in metabolic stability was obtained.
authors.affiliation: Pharmacokinetics, Pharmacodynamics, and Drug Metabolism (R.S.O., G.S.W.) and Worldwide Medicinal Chemistry (M.A.B.), Pfizer Inc., Groton, Connecticut and Cambridge, Massachusetts r.scott.obach@pfizer.com.
authors.forename: R Scott
authors.initials: RS
authors.lastname: Obach
authors.affiliation: Pharmacokinetics, Pharmacodynamics, and Drug Metabolism (R.S.O., G.S.W.) and Worldwide Medicinal Chemistry (M.A.B.), Pfizer Inc., Groton, Connecticut and Cambridge, Massachusetts.
authors.forename: Gregory S
authors.initials: GS
authors.lastname: Walker
authors.affiliation: Pharmacokinetics, Pharmacodynamics, and Drug Metabolism (R.S.O., G.S.W.) and Worldwide Medicinal Chemistry (M.A.B.), Pfizer Inc., Groton, Connecticut and Cambridge, Massachusetts.
authors.forename: Michael A
authors.initials: MA
authors.lastname: Brodney
mesh_terms: D000447:Aldehydes / Q000737:chemistry; D000068579:Celecoxib / Q000737:chemistry; D003577:Cytochrome P-450 Enzyme System / Q000378:metabolism*; D004048:Diethylamines / Q000737:chemistry; D005461:Fluorine / Q000737:chemistry*; D054879:Halogenation; D006801:Humans; D006900:Hydroxylation; D007192:Indenes / Q000737:chemistry; D009682:Magnetic Resonance Spectroscopy / Q000379:methods; D008862:Microsomes, Liver / Q000378:metabolism; D008874:Midazolam / Q000737:chemistry; D004364:Pharmaceutical Preparations / Q000737:chemistry*; D018967:Risperidone / Q000737:chemistry
chemical_list: D000447:Aldehydes; D004048:Diethylamines; D007192:Indenes; D004364:Pharmaceutical Preparations; D005461:Fluorine; C040394:diethylaminosulfur trifluoride; C495910:ramelteon; D003577:Cytochrome P-450 Enzyme System; D000068579:Celecoxib; D018967:Risperidone; D008874:Midazolam